Forest to develop Adamas’ memantine/donepezil combo for Alzheimer’s
Adamas Pharmaceuticals Inc. (optimized and controlled-release formulations of aminoadamantane compounds for CNS diseases) has licensed Forest Laboratories Inc. exclusive US development and marketing rights to its Phase III Arimenda, a fixed-dose, once-daily combination of extended-release memantine (which Forest sells as Namenda XR for moderate-to-severe Alzheimer’s disease) and immediate-release donepezil (Pfizer/Eisai’s Aricept) for moderate-to-severe dementia associated with Alzheimer’s.
- Controlled Release
- Drug Delivery
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com